KULDEEP CHOUDHARY

KULDEEP CHOUDHARY

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ACArvind Chopra
Arvind Chopra
GTGirish Tillu
Girish Tillu
KCKULDEEP CHOUDHARY
KULDEEP CHOUDHARY
GRGovind Reddy
Govind Reddy
ASAlok Srivastava
Alok Srivastava
BPBhushan Patwardhan
Bhushan Patwardhan
Objective: Evaluate the efficacy of AYUSH 64, a standard polyherbal Ayurvedic drug in COVID-19.Methods: During the first pandemic wave, 140 consenting and eligible hospitalized adult participants with mild-moderate symptomatic disease (specific standard RT-PCR assay positive) were selected as per a convenience sample, and randomized (1:1 ratio) to an open-label (assessor blind) two-arm multicentric drug trial; standard of care (SOC as per Indian guidelines) versus AYUSH 64 combined with SOC (AYUSH plus). Participants were assessed daily and discharged once clinical recovery (CR, primary efficacy) was achieved which was based on a predetermined set of criteria (resolution of symptoms, normal peripheral oximetry, and negative specific RT-PCR assay). Each participant was followed using an indigenous software program(mobile phone) and completed a 12-week study period. The dose of AYUSH 64 was 2 tablets oral, 500 mg each, bid for 12 weeks (AYUSH plus only). Significant P was <0.05 (two-sided). On randomization, the groups were found well matched.Results: The mean interval time from randomization to CR was significantly superior in the AYUSH plus group [mean 6.45 days versus 8.26 days, 95% Confidence Interval of the difference -3.02 to -0.59 (P = 0.003, Student’s ‘t test] as per-protocol analysis (134 participants); significant (P = 0.002) on an intention to treat analysis. 70% of the participants in AYUSH plus recovered during the first week (P = 0.046, Chi-square) and showed a significantly better change in physical health, fatigue, and quality of life measures. 48 adverse events, mostly mild and gut related, were reported by each group. There were 20 patient withdrawals (8 in AYUSH plus) but none due to an AE. There were no deaths. Daily assessment (hospitalization) and supervised drug intake ensured robust efficacy data. The open-label design was a concern (study outcome).Conclusions: AYUSH 64 in combination with SOC hastened recovery, reduced hospitalization, and improved health in COVID-19. It was considered safe and well-tolerated. Further clinical validation (Phase III) is required.Trial registration: CTRI/2020/06/025557.

20 September 2023 in Journal of Herbal Medicine
Verified
Journal Article
Open access
KCKULDEEP CHOUDHARY
KULDEEP CHOUDHARY
MGM. Gundeti
M. Gundeti
PDP. Dave
P. Dave
SGS. Goel
S. Goel
AAAZEEM AHMAD
AZEEM AHMAD
RAR. Acharya
R. Acharya

1 October 2022 in AYU (An International Quarterly Journal of Research in Ayurveda)
Verified
Journal Article
Closed access
KCKULDEEP CHOUDHARY
KULDEEP CHOUDHARY
STSaketh Ram Thrigulla
Saketh Ram Thrigulla
MGManohar S. Gundeti
Manohar S. Gundeti
PMPratyusha Mantena
Pratyusha Mantena
SKShruti Koulgi
Shruti Koulgi
Narayanam SrikanthNarayanam Srikanth
Narayanam Srikanth
Background: Balachaturbhadra Churna (BC), Ayurvedic powder dosage form, has four ingredients (Aconitum heterophyllum Wall. Ex Royle, Pistacia integerrima stew. Ex brandis, Piper longum Linn., and Cyperus rotundus linn.), which is commonly prescribed for treating fever, cough, and diarrhea in a pediatric setting. Aim: The present study evaluates the possible antiviral effect of phytochemicals from the ingredients of BC on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (MPro), Ribose Nucleic Acid (RNA) dependent RNA polymerase (RdRP), and spike-angiotensin-converting enzyme 2 (SA) complex through in silico evaluation. Materials and methods: X-ray crystal structure of MPro and Spike-Ace (SA) complex with Protein Data Bank (PDB) IDs 6LU7 and 6LZG and the SWISS model of RdRP were used as the drug targets. An enhanced docking methodology has been implemented to perform the molecular docking of these phytochemicals against the above-mentioned drug targets of SARS-CoV-2. DOCK6 was used to perform the docking of these phytochemicals. The absorption, distribution, metabolism, excretion, and toxicity (ADMET) and drug likeliness properties for these selected phytochemicals were performed using SWISS ADME. Results: The ensemble docking studies suggest that aconitine, lappaaconitine from Aconitum heterophyllum Wall. Ex Royle, 2’-hydroxyisorientin from Pistacia integerrima stew. Ex brandis, and guineesine, pipercide and piperoic acid from Piper longum Linn. hold the potential to bind favorably with the SARS-CoV-2 drug targets. The drug-likeliness and ADMET properties were calculated for these phytochemicals indicating that all three phytochemicals from Piper longum were observed to have considerate drug-likeliness and ADMET properties. Aconitine has a molecular weight slightly higher than 500 kDA and has more than 10 hydrogen bond acceptors. Conclusion: The in silico study demonstrates that phytochemicals present in BC viz., aconitine, lappaaconitine from Aconitum heterophyllum, 2’-hydroxyisorientin from Pistacia intergerrima and guineesine, pipercide, and piperoic acid from Piper longum hold the potential to bind favourably with the SARS-CoV-2 drug targets. The study also provides evidence for drug likeliness and ADMET properties for these phytochemicals suggesting that BC can be further studied as a potential drug of choice for treating SARS-CoV-2 infection to avert post-infectious disease, characterized by multisystem inflammatory syndrome in children in rare cases and other similar conditions in the pediatric setting.

28 January 2016 in International Journal of Research in Ayurveda and Pharmacy
Verified
Journal Article
Open access
MGMonika Guleria
Monika Guleria
KCKULDEEP CHOUDHARY
KULDEEP CHOUDHARY
SSSanjeev Sharma
Sanjeev Sharma

31 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DDDyumn Dwivedi
Dyumn Dwivedi
BPBishal Patgiri
Bishal Patgiri
MCMaya Chaturvedi
Maya Chaturvedi
PSPallavi Somvanshi
Pallavi Somvanshi
HKHemant Ritturaj Kushwaha
Hemant Ritturaj Kushwaha
RCRupesh Chaturvedi
Rupesh Chaturvedi
Prakriti, the constitutionally determined phenotypic framework described in Ayurveda, is thought to capture biologically meaningful inter-individual variation in physiology, disease susceptibility and therapeutic response. Although prior Ayurgenomics studies have identified constitution-linked differences in gene expression, genetic variation and epigenetic state, the regulatory architecture underlying these phenotypes remains poorly understood. We applied a multi-layer systems biology framework to Prakriti-stratified bulk transcriptomic data. Weighted gene co-expression network analysis was used to identify Prakriti-associated modules and hub genes. Pathway activity was inferred using PROGENy and GSVA; transcription factor activity was estimated using VIPER; immune composition was assessed using ssGSEA, CIBERSORTx, and xCell; and immune-evasion markers were analysed using differential expression and clustering approaches. Dark kinase activity was profiled as a dedicated analytical layer, and cross-layer integration was performed using z-score-standardised feature matrices, correlation analysis, principal component analysis and linear interaction modelling. Eighteen co-expression modules were identified, of which three showed strong Prakriti associations: a Vata-linked module enriched for innate immune sensing and leukocyte trafficking, a Pitta-linked module enriched for chromatin regulation and ubiquitin-mediated proteolysis, and a Kapha-linked module enriched for RNA processing, DNA repair, adhesion and calcium-channel biology. PROGENy revealed a largely shared inflammatory and hypoxic macro-state across constitutions, indicating that broad canonical signalling did not itself explain group separation. Finer-resolution analyses uncovered marked divergence across regulatory layers. Vata combined innate immune activation with strong immunosuppressive features, including selective elevation of IDO2, ARG1, TGFB3, SIGLEC15 and CD274. Pitta showed mitochondrial and proteostatic signatures together with dominant PDCD1LG2 expression. Kapha displayed the most consistent GSVA elevation across immune-metabolic pathways and was enriched for M2 macrophages, NKT cells and B cells. Dark kinome profiling identified reciprocal constitutional patterns: ALPK3 and STK31 were enriched in Kapha, and BRSK1, WNK2, and STKLD1 were enriched in Vata. Cross-layer integration revealed a coherent TNFa/NFkB-to-AP1 regulatory bridge. It showed that dark kinase activity was significantly coupled to immune-evasion outputs, with checkpoint regulation displaying a Prakriti-dependent interaction that reversed in Pitta relative to Kapha. Prakriti-associated molecular divergence is not primarily encoded in isolated genes or broad pathway shifts, but in constitution-specific regulatory wiring across co-expression, transcription factor, immune, metabolic and dark kinase-linked layers. These findings move Ayurgenomics beyond descriptive stratification towards a systems-level mechanistic framework for constitutional biology and provide a basis for future validation in precision immunology and personalised medicine.

17 September 2021 in OSF Preprints
Verified
Preprint
Open access
ACArvind Chopra
Arvind Chopra
PRPrasanna Kumar Rao
Prasanna Kumar Rao
RRR. Govind Reddy
R. Govind Reddy
MGManohar Gundeti
Manohar Gundeti
KCKULDEEP CHOUDHARY
KULDEEP CHOUDHARY
BPBhushan Patwardhan
Bhushan Patwardhan
Objectives: Comparative study of Ashwagandha (Withania somnifera; WS) and hydroxychloroquine (HCQ) for chemoprophylaxis against COVID-19 in actively engaged high-risk health-care workers. Design: Randomized, multicentric, open label, active control, two arm parallel efficacy study of 16 weeks. Sample size was based on pre-set 15% non-inferiority margin to HCQ for prophylaxis against COVID-19 with 80% power and alpha < 0.05. Participants: 400 health-care workers from three sites who were asymptomatic and tested negative for a quantitative Reverse Transcription Polymerase Chain Reaction test (RT-PCR) for COVID-19 and SARS-CoV-2 antibodies (IgG) were randomized in a 1:1 ratio. Participants observed physical protection measures as per the national policy. All incident confirmed COVID-19 were withdrawn.Interventions: Two tablets of 250 mg standardized aqueous extract of WS, twice daily after meal or HCQ 800 mg loading followed by 400 mg weekly for 16 weeks as per the national guidelines. Main outcome measures: The primary efficacy measure was “failure of prophylaxis” as confirmed by RT-PCR at any time during the study. Both intention-to-treat (ITT) and per-protocol (PP) efficacy analyses were performed.Results: 95 participants in the Ashwagandha (WS) arm and 101 participants in the HCQ arm completed the study. Both groups were well matched at the baseline. 91 participants from the Ashwagandha arm and 84 from the HCQ arm were withdrawn because they received the COVID-19 vaccination. Four participants (2%; 95% CI 2.8 to 3.9%) in the Ashwagandha and 5 (2.5%; 95% CI 5.4 to 8%) in the HCQ arm developed confirmed COVID-19. This was within the prefixed non-inferiority margin and the 95% CI of the absolute risk reduction (ARR) was -2.9 to 3.8% intention to treat (ITT) and -5.9 to 7.5% per protocol (PP). The 95% CI of ARR for the total COVID-19 cases was -2.8 to 11.9% ITT and -5.7 to 20.3% PP. Several health measures, particularly anxiety and stress, improved significantly in the Ashwagandha arm. Seven out of 117 in the Ashwagandha and 59 out of 178 in the HCQ groups were reported to be possible drug-related adverse events (AE); there were significantly less gut-related AE in the Ashwagandha group. AE were mostly mild and did not cause withdrawal. All incident COVID-19 cases recovered without complications. Conclusions: Ashwagandha was non-inferior to HCQ in the chemoprophylaxis against COVID-19 in high risk health-care workers. It was significantly safer, well tolerated and improved quality of life measures. Ashwagandha as COVID-19 prophylaxis seems appropriate in high-risk populations. Trial registration: The Clinical Trials Registry India Number CTRI/2020/08/027163 dated August 14, 2020.